



# Transforming health through the human microbiome

Q1 FY23 Results & Update

**October 2022** | *Authorised for release by the CEO & Chairman*

**ASX: MAP**



# Disclaimer

This presentation (**Presentation**) has been prepared by Microba Life Sciences Limited (**Microba**).

**Summary information** - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation. Microba may in its absolute discretion, but without being under any obligation to do so, update or supplement this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Microba or that would be required in a prospectus or other disclosure document prepared in accordance with the requirements of the *Corporations Act 2001* (Cth) (**Corporations Act**).

**Industry and market data** – In this Presentation, Microba refers to certain market, industry, and statistical data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither Microba nor its representatives have independently verified any such data and no representation or warranty, express or implied, is made as to its fairness, accuracy, correctness, completeness or adequacy. Some data is also based on the good faith estimates of Microba, which are derived its reviews of internal sources as well as the independent sources described above.

**Not an offer** - This Presentation is not a prospectus or other disclosure document under the Corporations Act and will not be lodged with the Australian Securities and Investments Commission. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this Presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions and should seek your own advice. Any non-compliance with these restrictions may contravene applicable securities laws.

**Not investment or medical advice** - The information contained in this Presentation is not investment, financial product advice, medical advice or any medical recommendation or recommendation to acquire Shares. This Presentation has been prepared without taking into account your investment objectives, financial situation, medical or any other particular needs. This Presentation does not and will not form any part of any contract for the acquisition of shares. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation. Before making an investment decision, you should consider whether it is a suitable investment for you in light of your own investment objectives, financial situation and particular needs and having regard to the merits or risks involved. Independent financial advice is recommended.

**Future performance** - This Presentation contains forward looking statements. Forward-looking statements generally relate to current expectations, hopes, beliefs, intentions, strategies or productions about future events or Microba's future financial or operating performance. For example, statements regarding anticipated growth in the industry in which Microba operates and anticipated growth in demand for Microba's products and services, projections of Microba's future financial results and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "pro forma", "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance and may involve known and unknown risks, uncertainties and other factors, many of which are outside the control of Microba. You are cautioned not to place undue reliance on any forward looking statement. Forward looking statements in this Presentation are based on assumptions and contingencies which are subject to change without notice. Actual results, performance or achievements may vary materially from any forward looking statements and the assumptions on which statements are based. The forward looking statements in this Presentation are based on information available to Microba as at the date of this Presentation and nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Except as required by law or regulation, Microba undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise.


**Financial data** – All dollar values in Australian dollars (A\$ or \$) unless otherwise stated. Recipients should note that this Presentation contains historical and pro-forma financial information. Any financial information provided in this Presentation is for illustrative purposes only and is not represented as being indicative of Microba's views on its future financial condition and/or performance.

**Trademarks** – This Presentation may contain trademarks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, trade names and copyrights referred to in this Presentation may be listed without the © or ® symbols, but Microba asserts, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, trade names and copyright.

**Disclaimer** - Except for any statutory liability which cannot be excluded, Microba, its related bodies corporate and their respective officers, employees and advisers expressly disclaim all liability (including negligence) for any direct or indirect loss or damage which may be suffered by any person in relation to, and take no responsibility for, any information in this Presentation or any error or omission therefrom, and make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of this Presentation.

# Microba's Commercial Model

Global testing services build a proprietary databank driving transformative novel therapies



# Company Snapshot



Continuous YoY  
**revenue growth** over  
5 years of operations



Partnerships with market leaders  
incl. **SYNLAB** (GR:SYAB),  
**Illumina** (NASDAQ: ILMN),  
**Genova Diagnostics**, and **G42**



**Large, unique, proprietary**  
microbiome databank



3 key therapeutic programs  
with lead IBD drug candidate  
**progressing to Phase 1 trial**



World-leading technology  
in the emerging **US\$4.89 billion**  
microbiome sector<sup>1</sup>



Globally **leading microbiome**  
**expertise** complemented by  
drug discovery experts including  
Prof. Ian Frazer

# Microbiome Services


Driving global revenues  
and data growth

# Expanding network of global distribution partners

Distribution agreements executed with global market leaders to distribute microbiome testing solutions powered by Microba’s world leading Analysis Platform technology.

						
<div><p><b>Metagenics</b></p></div> <div><p><b>AU &amp; NZ</b></p><ul style="list-style-type: none"><li>• Metagenics is a leader in functional nutrition</li><li>• Large allied health clinician customer base</li><li>• In 2019, the Company finalised a distribution partnership for AU &amp; NZ</li></ul></div>	<div><p><b>SYNLAB V</b></p></div> <div><p><b>Europe</b></p><ul style="list-style-type: none"><li>• Europe’s largest pathology company</li><li>• Presence in over 40 countries</li><li>• Manage 500m tests a year for 10m patients</li><li>• Expansion across key countries in Europe are ongoing</li></ul></div>	<div><p><b>GENOVA DIAGNOSTICS</b></p></div> <div><p><b>US</b></p><ul style="list-style-type: none"><li>• Leading GI pathology company</li><li>• &gt;10,000 purchasing clinicians</li><li>• In Dec 2021 the Company signed a distribution partnership for the US healthcare market</li><li>• In June 2022 operations commenced</li></ul></div>	<div><p><b>G42 HEALTHCARE</b></p></div> <div><p><b>Middle East</b></p><ul style="list-style-type: none"><li>• Leading health-tech company</li><li>• Harnessing data and advanced technologies for personalised care</li><li>• In Feb 2022 the Company signed a distribution partnership for the GCC region</li><li>• In June 2022 operations commenced</li></ul></div>	<div><p><b>00000 midnight.health</b></p></div> <div><p><b>AU</b></p><ul style="list-style-type: none"><li>• Fast growth innovative consumer healthcare company backed by nib</li><li>• In May 2022 the Company signed a partnership to deliver a world-first personalised consumer health service</li></ul></div>	<div><p><b>New partner</b></p></div>	<div><p><b>New partner</b></p></div>
<p><b>Launched Mid 2019</b></p>	<p><b>Launched Mid 2021</b></p>	<p><b>Launched Mid 2022</b></p>	<p><b>Launched Mid 2022</b></p>	<p><b>Launched Q3 2022</b></p>		

# Global distribution expansion driving growth post COVID



**>20**  
Leads


**10**  
Qualified opportunities

---

**18**  
Potential new countries

**4**  
Potential new US distributors

# Strategically aligned partners are **motivated and ramping up**



Search for

LOCATOR | BOND INVESTORS | SYNLAB IR

News & Publications | Diagnostics & Services | Partners of Expertise | About SYNLAB | Working for SYNLAB

Home / News & Publications / SYNLAB and Microba reinforce their ...

27 October 2022 | Press releases

## SYNLAB and Microba reinforce their combined expertise and expand strategic agreement on advanced gut microbiome test myBIOME



- Launched in Spain and Colombia in 2020, myBIOME is an innovative gut microbiome examination based on technology developed by Microba's leading researchers in the field of microbiome analysis.
- The combination of leading-edge comprehensive metagenomic sequencing and evidence-based reporting provides precise imaging of the gut microbiome.
- myBIOME provides a comprehensive analysis of the composition of an individual's gut microbiome and its functional potential to deliver personalized treatment or nutrition recommendations.
- Consumers and healthcare professionals alike benefit from the comprehensive gut microbiome analysis that myBIOME provides to detect the cause of a broad range of health complaints.
- SYNLAB and Microba are now extending the offering to wider distribution across Europe and Latin America.


Download press release

PDF | SYNLAB and Microba expand myBIOME agreement | EN

DOWNLOAD

PDF | SYNLAB und Microba erweitern strategische Zusammenarbeit für myBIOME | DE

DOWNLOAD



SIGN UP

Search Business News Australia...

## Midnight Health, Microba launch precision prebiotics subscription service Vidality

By Matt Ogg27 October 2022

A [partnership](#) between Brisbane-based companies Midnight Health and [Microba Life Sciences \(ASX: MAP\)](#) has borne fruit within five months with the launch of Vidality, a precision prebiotics subscription service for improving the gut microbiome.

The new offering adds to a prolific roll-out of services from [Midnight Health since it was founded in 2021](#), and comes shortly after a \$12 million Series A funding round in August from health fund Nib (ASX: NIB), which had earlier [pumped \\$4 million into the venture](#).

In late May, Microba and Midnight Health signed a three-year partnership to deliver personalised health services to the Australian market.

"Vidality is designed to transform how we understand and improve gut health in Australia," says Nic Blair, who co-founded Midnight Health with Matt Anderson, both winners of the [2022 Brisbane Young Entrepreneur Awards](#) in the Startup category.

"Every Australian has a diverse and unique microbiome, so rather than taking a one-size-fits-all approach, we are now enabling people to understand their unique gut health needs and access a prebiotic supplement that is specifically tailored to them.


"Vidality supports people through a holistic gut health journey that provides personalised analysis and results, educational resources and of course, access to our scientifically-developed pharmaceutical-grade Precision Prebiotics."



# **Microbiome Therapeutics**

Developing novel monoclonal  
microbial cell therapies

# Repeatable, scalable, data-driven platform **discovering novel monoclonal microbial cell therapies**



Proprietary microbiome databank driving **multiple therapeutic opportunities through a capital light platform**

# Key milestones upcoming for therapeutic programs

## Inflammatory Bowel Disease



### PROGRESSING TO PHASE I

#### Recently Completed

- ✓ Manufacturing scale up
- ✓ FDA Pre-IND meeting requested

#### Upcoming milestones

- FDA Pre-IND meeting
- Phase 1 HREC submission
- Phase 1 HREC approval
- cGMP manufacturing complete
- Phase 1 trial commencement



UNIVERSITY  
OF MIAMI



## Cancer Immunotherapy



### PRECLINICAL

#### Recently Completed

- ✓ Leads discovered
- ✓ Leads isolated

#### Upcoming milestones

- First animal model results
- Immunological MOA studies



Garvan Institute  
of Medical Research



Omico.

## Autoimmune Diseases



### SCREENING

#### Recently Completed

- ✓ Program commenced
- ✓ Strains provided to Ginkgo

#### Upcoming milestones

- First in vitro screening results



GINKGO BIOWORKS™  
THE ORGANISM COMPANY



# The start of a microbiome therapeutic revolution



**Q4 CY22 /Q1 CY23**  
**anticipated FDA approval**  
Feecal doner derived enema  
drug product




**H1 CY23**  
**anticipated FDA approval**  
Feecal doner derived oral  
capsule drug product



**FDA APPROVAL WOULD**  
**CLEAR THE PATH TO MARKET**  
**FOR LIVE MICROBIOME DRUGS,**  
**A NEW MODALITY.**

**First Generation**  
Fecal Doner Derived



**Second Generation**  
Bacterial Consortia



**Next Generation**  
Single Strain & Small Molecule




# Seres Therapeutics performance as FDA approval edges closer

DOW JONES  
NEWSWIRES

## Seres Therapeutics Shares Rise 18% After FDA Accepts BLA for SER-109

Published: Oct. 26, 2022 at 12:43 p.m. ET



# Outlook





# Upcoming Milestones for FY23

2022 OCT – DEC	2023 JAN - MAR	2023 APR - JUN
<div>Services</div> <div>New healthcare product full launch</div>		
<div>Services</div> <div>SYNLAB country expansion</div>		
<div>Services</div> <div>New international distribution deals</div>	<div>Services</div> <div>New international distribution deals</div>	
	<div>Therapeutics - IBD MAP315 program</div> <div>Phase 1 HREC Submission</div>	
	<div>Therapeutics - IBD MAP315 program</div> <div>FDA Pre-IND meeting outcome</div>	<div>Services</div> <div>New international distribution deals</div>
	<div>Therapeutics - IO Program</div> <div>Pre-clinical results</div>	<div>Therapeutics - IBD MAP315 program</div> <div>GMP manufacture complete for Ph1</div>
	<div>Therapeutics – Autoimmune Program</div> <div>First <i>in vitro</i> screening results</div>	<div>Therapeutics - IBD MAP315 program</div> <div>HREC Approval for Phase 1 trial</div>
		<div>Therapeutics - IBD MAP315 program</div> <div>Phase 1 trial commencement</div>

# Contact



**Dr Luke Reid**

Chief Executive Officer  
luke.reid@microba.com



**Pasquale Rombola**

Chairman  
pasquale.rombola@microba.com

## **Head Office**

Level 10, 324 Queen Street  
Brisbane QLD Australia

## **Laboratory**

Princess Alexandra Hospital  
Woolloongabba QLD Australia